What is MYGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.41B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MYGN?

P/E (TTM) is n/a and 52-week range is $2.74 to $8.59 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MYGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MYGN?

The company profile lists revenue (TTM) near $804M, net income (TTM) near $-11.22B, EPS (TTM) near $-1.20 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Myriad Genetics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Salt Lake City, Utah, US, 94.5M shares outstanding, ISIN US62855J1043 when available from company profile and filing metadata.

Myriad Genetics Inc

$MYGN

Health Care · Biotechnology

IR Run Scenarios

$4.31

+2.62%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Employees

2,700

Website

myriad.com/

IPO

1995-10-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)